19-羟基-4-雄甾烯-17-酮 | 121739-39-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 19-羟基-4-雄甾烯-17-酮
• 英文名称: 19-hydroxyandrost-4-en-17-one
• 英文别名: 19-Hydroxy-4-androsten-17-one；(8R,9S,10S,13S,14S)-10-(hydroxymethyl)-13-methyl-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
• CAS: 121739-39-7
• 化学式: C₁₉H₂₈O₂
• 分子量: 288.43
• InChiKey: UGCIHWZOIVCJGP-BGJMDTOESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  19-羟基-4-雄甾烯-17-酮 在 重铬酸吡啶 、 对甲苯磺酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 10.0h， 生成 17,17-(ethylenedioxy)androst-4-en-19-al
  参考文献：
  名称：

  Synthesis and biochemical studies of 16- or 19-substituted androst-4-enes as aromatase inhibitors

  摘要：

  Androst-4-en-17-one derivatives [19-acetoxide 4, 16-bromides 14 and 15, 19,19-difluoride 18, and (19R,S)-19-acetylenic alcohol 25] and androst-4-en-17-beta-ol derivatives 3, 5, 10, 12, and 19 were synthesized and tested for their ability to inhibit aromatase in human placental microsomes. All the 17-oxo steroids, except compound 25 and 17,19-diol 3 of this series, were effective competitive inhibitors with apparent K(i)'s ranging from 170 to 455 nM. 19,19-Difluoro steroid 18 and 19-acetylenic alcohol 25, a weak competitive inhibitor (K(i) = 7.75-mu-M), caused a time-dependent, pseudo-first-order inactivation of aromatase activity with k(inact)'s of 0.0213 and 0.1053 min-1 for compounds 18 and 25, respectively. NADPH and oxygen were required for the time-dependent inactivation, and the substrate, androst-4-ene-3,17-dione, prevented it, but a nucleophile, L-cysteine, did not in each case. The results strongly suggest that aromatase would attack the 19-carbon of steroids 18 and 25.

  DOI：

  10.1021/jm00112a028
• 作为产物：
  描述：

  19-羟基雄甾-4-烯-3,17-二酮 在 四丙基高钌酸铵 、 乙醇 、 氨 、 sodium 、 4-甲基苯磺酸吡啶 、 对甲苯磺酸 、 N-甲基吗啉氧化物 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 20.36h， 生成 19-羟基-4-雄甾烯-17-酮
  参考文献：
  名称：

  3-脱氧雄激素的合成及化学模型反应研究：证据支持人类胎盘芳香化酶催化2、3-烯醇化假说

  摘要：

  许多迄今未描述的Δ 2 -和Δ 3 -3脱氧5α雄激素衍生物（17β，19-二醇12和13，19-羟基-17-酮16和17，19氧代-17-酮18和19）以高收率合成。锂-氨还原的19-（四氢吡喃-2-基氧基）雄甾-4-烯-3- -3,17-二酮7接着夏皮罗反应允许易于施工两个Δ的2 -和Δ 3 -3脱氧5α类固醇系统。已知的Δ的改进的合成4 -3- deoxyandrogen衍生物（28，30，31）以高产量完成。19位羟基的掩蔽，以产生Δ是必要4以良好的收率-3- deoxyandrogen系统，在对比的是帐户化合物的早期合成的28和30通过Numazawa。在芳香动作第三氧化处理的化学模型进行反应与Δ 2 - ，Δ 3 - ，Δ 4 -和Δ 2,4 -3-脱氧-19-氧代- 17-酮甾族化合物（18，19，31和5分别）。结果示出了用于两个Δ需要2 -和Δ 4，以便产生Δ-unsat

  DOI：

  10.1039/p19940002237

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Aromatization of androstenedione and 16α-hydroxyandrostenedione in human placental microsomes
  作者：Mitsuteru Numazawa、Yoko Watari、Sachiko Komatsu、Kouwa Yamashita、Masao Nagaoka

  DOI：10.1016/j.steroids.2008.06.001

  日期：2008.11

  Inhibition of aromatase activity in human placental microsomes with androstenedione (AD) (1a) and its 19-oxygenated derivatives 1b and 1c, their 16a-hydroxy compounds 2 and 3, and 3-deoxyandrost-4-ene compounds 5 and 6 was studied using [1 beta-(3)H]AD as a substrate and compared to that with [1 beta-(3)H]16 alpha-hydroxyandrostenedione (16-OHAD). AD series of steroids, compounds 1, inhibited competitively [1 beta-(3)H]AD aromatization whereas other 16a-hydroxy steroids 2, 3, S, and 6 inhibited AD aromatization in a non-competitive manner. On the other hand, all of 16-OHAD series, compounds 2, blocked the [1 beta-(3)H]16-OHAD aromatization in a competitive manner whereas the AD series steroids 1 as well as the 3-deoxy-16 alpha-hydroxy-17-one steroids 5 and 3-deoxy-16 alpha,17 beta-diol steroids 6 inhibited 16-OHAD aromatization non-competitively. 3-Carbonyl and 16 alpha-hydroxy functions of 16-OHAD play a critical role of selection of the 16-OHAD binding site. The results suggest that the AD derivatives 1 are kinetically aromatized at a different site from the 16-OHAD derivatives 2. Physical and/or chemical environments around the aromatase protein in the microsomal membrane may play a significant role in the expression of the substrate specificity, and the present results do not exclude the idea that the placental microsomes have a single binding site. (C) 2008 Elsevier Inc. All rights reserved.
• NUMAZAWA, MITSUTERU;MUTSUMI, AYAKO;HOSHI, KUMIKO;OSHIBE, MARIKO;ISHIKAWA,+, J. MED. CHEM., 34,(1991) N, C. 2496-2504
  作者：NUMAZAWA, MITSUTERU、MUTSUMI, AYAKO、HOSHI, KUMIKO、OSHIBE, MARIKO、ISHIKAWA,+

  DOI：——

  日期：——
• JPH02108696A
  申请人：——

  公开号：JPH02108696A

  公开（公告）日：1990-04-20
• Compositions and methods for treatment of viral diseases
  申请人：Johansen Lisa M.

  公开号：US20080161324A1

  公开（公告）日：2008-07-03

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.